Sign inJoin waitlistJoin the waitlist

Tanyanika Phillips

2019–Present, Antelope Valley Medical Center Oncology, Program Director · City of Hope National Medical Center

Credentials: · · · · · · ·

History

2019–present, Antelope Valley Medical Center Oncology · City of Hope National Medical Center
Present
City of Hope National Medical Center
Present
City of Hope National Medical Center
Present

Geriatric Medicine
Vanderbilt University Medical Center
2002–2003
Vanderbilt University Medical Center
2001–2002
Internal Medicine
Ochsner Clinic Foundation
1998–2001
Vanderbilt University
University of Rochester School of Medicine and Dentistry
1994–1998

Research

Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
Journal of Clinical Oncology · 2018 · 2,915 citations
Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update
Journal of Clinical Oncology · 2021 · 1,863 citations
Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update
Systematic review or meta-analysis · Journal of Clinical Oncology · 2017 · 1,578 citations

Ishmael Jaiyesimi
10 papers
Bryan Schneider
9 papers
DS
David Spigel
6 papers
DJ
Dharamvir Jain
6 papers
Gregory Masters
6 papers
GR
Gregory Riely
6 papers
HM
Hirva Mamdani
6 papers
Julie Brahmer
5 papers
WD
William Dale
5 papers
AM
Amartej Merla
4 papers
CP
Cary Presant
4 papers
David Johnson
4 papers

Clinical trials

Adding the Immunotherapy Drug Cemiplimab to Usual Treatment for People With Advanced Non-Small Cell Lung Cancer Who Had Previous Treatment With Platinum Chemotherapy and Immunotherapy (An Expanded Lung-MAP Treatment Trial)
Site PI · Recruiting · Phase 2, Phase 3
SWOG Cancer Research Network
2025–2028
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
Site PI · Recruiting · Phase 2, Phase 3
SWOG Cancer Research Network
2019–2029